



US 20210284706A1

(19) **United States**(12) **Patent Application Publication**
Krupnick et al.(10) **Pub. No.: US 2021/0284706 A1**(43) **Pub. Date: Sep. 16, 2021**(54) **COMPOSITIONS AND METHODS FOR
TARGETED CYTOKINE DELIVERY**(71) Applicant: **Washington University**, St. Louis, MO
(US)(72) Inventors: **Alexander Sasha Krupnick**, St. Louis,
MO (US); **Daved Henry Fremont**, St.
Louis, MO (US); **Eric Reed Lazear**,
St. Louis, MO (US); **John Westwick**,
Houston, TX (US)(21) Appl. No.: **17/238,995**(22) Filed: **Apr. 23, 2021****Related U.S. Application Data**(63) Continuation of application No. 16/075,069, filed on
Aug. 2, 2018, filed as application No. PCT/US2017/
016688 on Feb. 6, 2017.(60) Provisional application No. 62/292,046, filed on Feb.
5, 2016, provisional application No. 62/342,630, filed
on May 27, 2016, provisional application No. 62/350,
056, filed on Jun. 14, 2016, provisional application
No. 62/419,146, filed on Nov. 8, 2016.**Publication Classification**(51) **Int. Cl.**
C07K 14/55 (2006.01)
C07K 14/54 (2006.01)**A61P 35/00** (2006.01)**A61K 47/68** (2017.01)**C07K 16/28** (2006.01)**C07K 14/705** (2006.01)**C07K 14/52** (2006.01)**C07K 14/545** (2006.01)**A61K 38/00** (2006.01)(52) **U.S. Cl.**CPC **C07K 14/55** (2013.01); **C07K 14/5443**
(2013.01); **A61P 35/00** (2018.01); **C07K**
14/5418 (2013.01); **A61K 38/00** (2013.01);
C07K 16/2851 (2013.01); **C07K 14/70596**
(2013.01); **C07K 14/52** (2013.01); **C07K**
14/545 (2013.01); **A61K 47/6849** (2017.08)

(57)

ABSTRACT

The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to an NKG2D ligand or PD1 ligand and may improve immunotherapy by limiting side effects associated with immunotherapy. The present disclosure also encompasses compositions and methods for recruiting cytotoxic lymphocytes to target cells using NKG2D receptor ligands or PD1 ligands. The compositions disclosed herein comprise a NKG2D receptor ligand and a targeting molecule and may improve immunotherapy by limiting side effects associated with immunotherapy.

Specification includes a Sequence Listing.